CD33 antibody | WM53
Filter by Application:F IP WB Reset
|Mouse anti Human CD33 antibody, clone WM53 recognizes the human CD33 cell surface glycoprotein. This antigen, considered to be specific for the myeloid lineage, has also been reported to be present on cells of lymphoid origin.
Mouse anti Human CD33 antibody, clone WM53 immunoprecipitates a protein of ~75 kDa from myeloid cells, a smaller protein of approximately 67 kDa has been observed in immunoprecipitates from lymphoid targets.
- Target Species
- Product Form
- Purified IgG conjugated to StarBright Violet 515 - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% sodium azide (NaN3)
1% bovine serum albumin
0.1% Pluronic F68
0.1% PEG 3350
- Human AML cells
- Fusion Partners
- Spleen cells from immunized BALB/c mice were fused with cells of the mouse NS1 myeloma cell line
- Max Ex/Em
Fluorophore Excitation Max (nm) Emission Max (nm) StarBright Violet 515 401 516
- For research purposes only
- 12 months from date of despatch
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
DO NOT FREEZE.
This product should be stored undiluted.
|Application Name||Verified||Min Dilution||Max Dilution|
- Flow Cytometry
- Use 5μl of the suggested working dilution to label 106 cells in 100μl. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
How to Use the SpectraviewerWatch the Tool Tutorial Video ▸
- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
References for CD33 antibody
Favaloro, E.J. et al. (1987) Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, gp67 (CD-33).
Dis Markers. 5 (4): 215-25.
Favaloro, E.J. et al. (1988) Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33.
Br J Haematol. 69 (2): 163-71.
Hernández-Caselles, T. et al. (2006) A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing.
J Leukoc Biol. 79: 46-58.
Biedermann, B. et al. (2006) Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors.
Leuk Res. 31: 211-20.
Lajaunias, F. et al. (2005) Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling.
Eur J Immunol. 35: 243-51.
Pietschmann, P. et al. (2000) Surface markers and transendothelial migration of dendritic cells from elderly subjects.
Exp Gerontol. 35: 213-24.
Favaloro, E.J. et al. (1993) Differential expression of surface antigens on activated endothelium.
Immunol Cell Biol. 71:571-81.
Yasukawa, T. et al. (2012) Simple detection of surface antigens on living cells by applying distinct cell positioning with negative dielectrophoresis.
Anal Chem. 84 (20): 8830-6.
View The Latest Product References
Hu, Z. et al. (2016) Self-assembled nanoparticles based on folic acid modified carboxymethyl chitosan conjugated with targeting antibody
J Wuhan Univ of Technol-Mater. Sci. Ed. 31 (2): 446-53.
Dahl C et al. (2004) Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro.
Allergy. 59 (10): 1087-96.
Vamvakopoulos, J.E. & Green, C. (2003) HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection.
BMC Cardiovasc Disord. 3: 6.
Vamvakopoulos, J. et al. (2002) Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist.
Eur J Immunol. 32 (10): 2988-96.
Lin, C.W. et al. (2005) CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features.
Blood. 106 (10): 3567-74.
McCormack E et al. (2013) Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
Blood. 121 (7): e34-42.
Hernández-Caselles T et al. (2019) CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway.
J Immunol Res. 2019: 6032141.
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up